| Name | Title | Contact Details |
|---|
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.
Drive tangible savings to your bottom line in weeks versus months using Valify, the only SaaS analytics and benchmarking tool for Purchased Services. Leave manual data aggregation behind. Automate the discovery of opportunity and begin tracking performance so your team can focus on realizing savings.
Impact Advisors is a nationally recognized healthcare consulting firm that is solving some of the toughest challenges in the industry by delivering strategic advisory, implementation and optimization services. Our comprehensive suite of patient access, clinical and revenue cycle services span the lifecycle of our clients` needs. Our experienced team has a powerful combination of clinical, revenue, operations, consulting, and IT experience. The firm has earned a number of prestigious industry and workplace awards including Best in KLAS® for thirteen consecutive years, Healthcare Informatics HCI 100, Crain`s Chicago Business Fast Fifty, as well as multi-year “best place to work” awards from: Modern Healthcare, Consulting Magazine, Becker`s Hospital Review and Achievers.
Healthtech Services is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chicago Hospital News is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.